Financial Performance - The company's operating revenue for Q1 2025 was CNY 305,640,342.42, a decrease of 2.97% compared to CNY 314,990,089.28 in the same period last year[4] - Net profit attributable to shareholders was CNY 60,590,351.64, down 19.22% from CNY 75,010,084.96 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 46,468,704.84, a decrease of 10.79% compared to CNY 52,091,879.13 in the previous year[4] - The net profit for Q1 2025 was CNY 60,590,351.64, a decrease of 19.3% compared to CNY 75,010,084.96 in Q1 2024[20] - Operating profit for Q1 2025 was CNY 62,469,083.72, down from CNY 80,220,974.65 in the same period last year, reflecting a decline of 22.1%[20] - The company reported a net profit margin of approximately 15.1% for Q1 2025, based on the revenue and operating costs figures[19] - The total comprehensive income for Q1 2025 was CNY 60,590,351.64, a decrease of 19.3% from CNY 75,010,084.96 in Q1 2024[21] Cash Flow and Investments - The net cash flow from operating activities was CNY 48,957,799.77, down 31.90% from CNY 71,892,080.50 year-on-year[4] - The cash flow from operating activities for Q1 2025 was CNY 48,957,799.77, a decrease of 32.0% compared to CNY 71,892,080.50 in Q1 2024[24] - The company reported a net cash outflow from investing activities of CNY 551,307,978.14 in Q1 2025, compared to a net inflow of CNY 41,296,601.12 in Q1 2024[24] - Cash and cash equivalents as of March 31, 2025, were RMB 496,753,707.66, down from RMB 971,404,996.50 as of December 31, 2024[14] - Cash and cash equivalents at the end of Q1 2025 were CNY 490,995,537.76, down from CNY 816,632,829.91 at the end of Q1 2024[25] Research and Development - Research and development expenses totaled CNY 61,855,238.88, representing 20.24% of operating revenue, an increase of 0.19 percentage points compared to 20.05% last year[5] - Research and development expenses rose to CNY 61,097,854.94 in Q1 2025, up 12.5% from CNY 54,184,914.96 in Q1 2024[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,460,845,346.04, an increase of 1.79% from CNY 3,400,127,500.60 at the end of the previous year[5] - Total assets increased to RMB 3,460,845,346.04 as of March 31, 2025, compared to RMB 3,400,127,500.60 at the end of 2024[16] - Total liabilities decreased slightly to RMB 697,883,870.78 from RMB 702,205,924.57 at the end of 2024[17] - Shareholders' equity increased to RMB 2,762,961,475.26 as of March 31, 2025, compared to RMB 2,697,921,576.03 at the end of 2024[17] - Inventory as of March 31, 2025, was RMB 213,618,891.26, up from RMB 190,086,164.97 at the end of 2024[15] - Short-term borrowings increased to RMB 103,385,606.87 from RMB 74,437,854.77 at the end of 2024[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,091[10] - The largest shareholder, Wang Ying, holds 34.89% of the shares, totaling 61,593,000 shares[11] Earnings Per Share - The basic and diluted earnings per share for Q1 2025 were both CNY 0.34, down from CNY 0.43 in Q1 2024[21] Financial Expenses - The company incurred financial expenses of CNY -1,829,246.74 in Q1 2025, compared to CNY -944,567.73 in Q1 2024, indicating an increase in financial costs[20]

Financial Performance - The company achieved operating revenue of CNY 1,349,755,302.66 in 2024, representing a year-on-year increase of 20.82%[23] - Net profit attributable to shareholders reached CNY 238,234,159.30, up 5.15% compared to the previous year[23] - The net profit after deducting non-recurring gains and losses was CNY 174,764,929.24, reflecting a growth of 10.90% year-on-year[23] - The net cash flow from operating activities was CNY 263,240,369.25, a decrease of 4.36% from the previous year[24] - The company's total assets increased to CNY 3,400,127,500.60, marking a 1.59% rise compared to the end of 2023[24] - Basic earnings per share rose to CNY 1.36, an increase of 6.25% from the previous year[25] - The company reported a significant growth in the CMO/CDMO business, with revenue soaring by 111.59% to CNY 65.20 million[38] - The company achieved total operating revenue of CNY 1,349,755,302.66, representing a year-on-year growth of 20.82%[126] - The net profit attributable to shareholders was CNY 238,234,200, reflecting a year-on-year increase of 5.15%[126] Research and Development - The R&D expenditure accounted for 21.31% of operating revenue, a decrease of 0.72 percentage points from the previous year[25] - Total R&D investment reached approximately CNY 287.62 million, an increase of 16.88% compared to the previous year, with a significant rise in capitalized R&D investment by 212.86%[89] - The company invests over 20% of its revenue in R&D, with nearly 30% allocated to innovative drugs, surpassing the industry average[72] - The company has established six drug research institutes across Chengdu, Meishan, and Shanghai, covering the entire pharmaceutical value chain[105] - The company is focusing on innovative synthesis techniques to enhance product quality and reduce environmental impact, particularly in the production of raw materials[102] - The company has made significant progress in its R&D pipeline, with one Class 1 new drug entering Phase III clinical trials and three Class 1 innovative drugs receiving clinical trial approvals[165] - The company has 19 products under review for market approval, with 11 products approved for clinical trials[171] - The company has a total of 31 raw materials under review for market approval, indicating a strong pipeline[172] Product Development and Market Expansion - The company plans to continue expanding its market presence and enhancing its product offerings in the coming years[26] - The company has launched new products, including Nalbuphine Hydrochloride Injection, with successful market access in multiple provinces[47] - The company is actively pursuing market expansion through innovative product development and strategic partnerships[10][12] - The company is focusing on expanding its product offerings in cardiovascular and respiratory treatments, with multiple new drugs in the pipeline[166] - The company has submitted multiple product applications, including EP-0124A+EP-0160I and EP-0125SP, with market potential in the U.S. and Europe[102] - The company has submitted registration applications for multiple new products, including a compound morphine sustained-release capsule and a new formulation of apatinib, with expected market entry soon[10][12][13] Compliance and Governance - The company has a standard unqualified audit report from the accounting firm Xin Yong Zhong He[6] - The company has no non-operating fund occupation by controlling shareholders or related parties[9] - The company has no violations of decision-making procedures regarding external guarantees[10] - The company has not disclosed any special arrangements for corporate governance[8] - The company has strengthened its quality management system, passing 13 GMP compliance checks and receiving multiple awards for quality management excellence[45] - The company is enhancing compliance management systems in response to stricter anti-corruption measures in the pharmaceutical industry[158] Market Trends and Industry Insights - The pharmaceutical manufacturing industry in China achieved a revenue of CNY 25,298.5 billion in 2024, with a profit of CNY 3,420.7 billion, reflecting a year-on-year profit decline of 1.1%[64] - The profit margin for the pharmaceutical manufacturing industry is approximately 13.52%, which is 8.13 percentage points higher than the overall level of large-scale industrial enterprises[64] - The global pharmaceutical market is projected to reach $2.3 trillion by 2028, with a CAGR of 5-8%[192] - China's pharmaceutical market has grown from $103 billion in 2014 to $163 billion in 2023, expected to reach $197 billion by 2028, with a CAGR of 3.8%[196] - The market share of innovative drugs in China increased from 20% in 2014 to 29% in 2023, with a projected CAGR of 7.5% for the next five years[197] Strategic Initiatives - The company is actively pursuing mergers and acquisitions, supported by recent government policies aimed at promoting high-quality development in the capital market[80] - The company is focusing on high-end formulations to navigate the complex market environment, driven by ongoing centralized procurement and DRG/DIP payment reforms[158] - The company aims to improve overall cost management and refine operations to support high-quality and differentiated development[159] - The company is committed to a research and development philosophy centered on creating differentiated clinical advantages, aiming to strengthen market competitiveness[159] Risk Management - The company has detailed various risks in its operations and has outlined measures to mitigate these risks in the management discussion section[5] - The company faces risks from national centralized procurement policies, which may lead to price reductions and impact operational performance[116] - The company faces risks from intensified competition in the pharmaceutical industry, particularly from Indian manufacturers and domestic market saturation[122] - The company is adapting to regulatory changes in the pharmaceutical industry, which may impact operational strategies and profit margins[120]

成都苑东生物制药股份有限公司 董事会审计委员会对会计师事务所 履行监督职责情况报告 成都苑东生物制药股份有限公司（以下简称公司）聘请信永中和会计师事务 所（特殊普通合伙）（以下简称"信永中和"）作为公司 2024 年度年报审计师。 根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事务 所管理办法》等规定和要求，公司董事会审计委员会本着勤勉尽责的原则，恪尽 职守，认真履职。现将董事会审计委员会对会计师事务所履行监督职责的情况汇 报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 信永中和最早可追溯到 1986 年成立的中信会计师事务所，于 2012 年由有限 责任公司转制为特殊普通合伙制事务所，注册地址为北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层，首席合伙人为谭小青先生。信永中和拥有财政部颁发的 会计师事务所执业证书，2010 年成为首批获准从事 H 股企业审计业务的会计师 事务所，新证券法实施前具有证券、期货业务许可证，2020 年在财政部完成从 事证券服务业务会计师事务所备案。 截至 2024 年 12 月 31 日，信永中和合伙人（股东）259 人， ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-018 成都苑东生物制药股份有限公司 关于2025年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次关联交易属于公司董事会决策权限，无需提交股东大会审议。 本次关联交易是基于公司正常生产、经营活动需要而进行的合理预计， 是公司合理利用资源的重要手段，定价政策严格遵循公开、公平、公正、等价有 偿的一般商业原则，有利于公司相关业务的开展，不会对公司持续经营能力、盈 利能力及资产独立性等产生不利影响，不存在对关联人形成较大依赖的情形。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 成都苑东生物制药股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开第四届董事会第二次会议及第四届监事会第二次会议审议通过了《关于公司 2025 年度日常关联交易预计的议案》，关联董事王颖女士、赵立文先生对本议 案进行了回避表决。该议案已经公司第四届董事会独立董事第一次会议审议通过 并提交公司董事会审议，属于公 ...

M 苑东生物 股票代码 | 688513 2025年度 提质增效重回报 行 动 方 案 前 言 成都苑东生物制药股份有限公司（以下简称或"公司"）为践行"以投资者为本"的上市 公司发展理念，助力资本市场稳定和经济高质量发展，基于对未来发展前景的信心及价值 的认可,于2024年4月23日发布了《2024年度"提质增效重回报"行动方案》,自行动方 案发布后,公司积极开展和落实相关措施,并于2024年8月20日发布了《2024年度"提质 增效重回报"行动方案半年度评估报告》。 为切实维护全体股东利益，公司制定了《2025年度"提质增效重回报"行动方案》， 全面评估了2024年度行动方案的执行情况，并制定了2025年度的优化措施，以推动公司 持续规范经营, 树立良好的资本市场形象。本方案已经公司第四届董事会第二次会议审议 通过。 2024绩效亮点 营业收入 净利润 同比 同比 增长 增长 扣非净利润 研发投入 注: 公司于2024年5月实施为期三年的员工持股计划及限制性股票激励计划,报告期内共计提股权激励费用2,012.29万元,剔除 股权激励费用影响, 归属于上市公司股东的净利润较上年同期增长13.47%, 归属于 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-015 成都苑东生物制药股份有限公司 关于开展票据池业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开第四届董事会第二次会议及第四届监事会第二次会议，审议通过了《关于开展 票据池业务的议案》，同意公司及下属子公司与金融机构开展不超过人民币 10,000 万元额度的票据池业务，即与国内商业银行合作开展票据池业务即期余额 不超过人民币 10,000 万元，有效期 18 个月，业务期限内该额度可滚动使用。现 将相关情况公告如下： 一、情况概述 （一）业务概述 票据池业务是指协议银行为满足企业客户对所持有的商业汇票进行统一管 理、统筹使用的需求，向企业提供的集票据托管和托收、票据质押池融资、票据 贴现、票据代理查询、业务统计等功能于一体的票据综合管理服务。 （二）合作银行 公司拟根据实际情况及具体合作条件选择资信较好的国内商业银行作为票 据池业务的合作银行，具体合作银行由 ...

成都苑东生物制药股份有限公司 第四届独立董事专门会议第一次会议决议 成都苑东生物制药股份有限公司（以下称"公司"）第四届独立董事专门会议 第一次会议通知于 2025 年 4 月 11 日以电话等方式临时向全体独立董事发出，会 议于 2025 年 4 月 14 日以通讯表决方式召开。本次会议应出席独立董事 3 名，实 际出席独立董事 3 名。经过半数独立董事推举，独立董事彭龙先生召集并主持本 次会议。本次会议的召集、召开及表决程序符合《上市公司独立董事管理办法》 等法律法规、规范性文件和《成都苑东生物制药股份有限公司章程》的规定，会 议形成的决议合法有效。 经全体与会独立董事审议：本次关联交易是基于公司及合并报表范围内子公 司正常生产、经营活动所必要的，是公司合理利用资源的重要手段。各项日常关 联交易的定价政策严格遵循公开、公平、公正、等价有偿的一般商业原则，有利 于公司相关业务的开展，不会对公司持续经营能力、盈利能力及资产独立性等产 生不利影响，不存在对关联人形成较大依赖的情形，符合有关法律法规及《公司 章程》的规定，不存在损害公司和公司股东利益，特别是中小股东的利益的情形。 我们同意将该关联交易事项提交公司 ...

成都苑东生物制药股份有限公司董事会 2025 年 4 月 24 日 根据《上市公司独立董事管理办法》、《上海证券交易所科创板股票上市规则》、 《上海证券交易所科创板上市公司自律监管指引第 1 号--规范运作》等相关法律 法规的规定，成都苑东生物制药股份有限公司（以下简称"公司"）董事会，就公 司现任独立董事方芳、彭龙、程增江的独立性情况进行评估并出具如下专项意见： 经核查独立董事方芳、彭龙、程增江的任职经历以及签署的相关自查文件， 公司独立董事及其直系亲属、主要社会关系均未在公司及其附属企业担任除独立 董事之外的其他职务；没有为公司及其附属企业提供财务、法律、管理咨询、技 术咨询等服务；除独立董事津贴外，没有从公司及其主要股东或有利害关系的机 构和人员处取得额外的、未予披露的其他利益，能够进行客观、独立的专业判断， 不存在影响独立性的情况。公司独立董事符合《上市公司独立董事管理办法》、 《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》等规定中对 独立董事独立性的相关要求。 成都苑东生物制药股份有限公司 董事会对独立董事独立性自查情况的专项报告 ...

成都苑东生物制药股份有限公司 2024 年度募集资金存放与使用情况的专项报告 （二） 募集金额使用情况和结余情况 截至 2024 年 12 月 31 日，结余募集资金（含利息收入扣除银行手续费的净 额）余额为 1,981.33 万元。 | 具体情况如下（单位：人民币万元）： | | --- | 项目 金额 募集资金总额 133,479.24 减：券商承销佣金及保荐费 9,091.18 收到募集资金总额 124,388.06 减：以募集资金置换预先投入自筹资金的金额 10,669.29 减：以募集资金置换预先支付发行费用的金额 726.00 1 本报告中的募集资金净额 1,222,708,416.51 元与验资报告中的募集资金净额 1,222,700,659.41 元 差异 7,757.10 元，系计划发行费用与实际存在差异：1.实际发行报告制作费用较预计减少 9,433.93 元；2.实际印花税较预计增加 1,676.83 元。 | 项目 | | 金额 | | --- | --- | --- | | 减：支付不含税发行费用的金额 | | 1,391.21 | | 减：直接投入募集项目的金额 | | 96,76 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-016 成都苑东生物制药股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于 2025年4月24日召开第 四届董事会第二次会议及第四届监事会第二次会议审议通过了《关于使用闲置自有 资金进行现金管理的议案》，同意公司及下属子公司自公司董事会审议通过之日起 18个月内使用不超过人民币15亿元的闲置自有资金进行现金管理，产品风险等级为 低风险（对应金融机构内部评级为R1、PR1或其他等同于低风险的评级级别）、中 低风险（对应金融机构内部评级为R2、PR2或其他等同于中低风险的评级级别）， 其中购买中低风险的非保本理财产品额度不得超过3亿元。董事会授权总经理行使 该项决策权及签署相关法律文件，具体事项由公司财务部负责组织实施。本事项属 于公司董事会决策权限范围内，无需提交公司股东大会审议。现将相关情况公告如 下： 一、本次使用闲置自有资金进行现金管理的情况 （一）投资产 ...